Literature DB >> 32569408

7T MPFLAIR versus MP2RAGE for Quantifying Lesion Volume in Multiple Sclerosis.

Margaret Spini1, Seongjin Choi2, Daniel M Harrison2,3.   

Abstract

BACKGROUND AND
PURPOSE: Use of fluid-attenuated inversion recovery (FLAIR) scans to quantify multiple sclerosis (MS) lesion volume on 7 Tesla (7T) magnetic resonance imaging (MRI) has many downsides, including poor image homogeneity. There are little data about the relative benefit of alternative modalities. The purpose of this paper is to investigate if magnetization-prepared 2 rapid acquisition gradient echo (MP2RAGE) is a viable alternative to FLAIR for robust lesion volume measurement and disability correlations.
METHODS: Forty-seven participants with MS underwent annual brain 7T MRIs. Magnetization-prepared FLAIR (MPFLAIR) and MP2RAGE (both at .7 mm3 isotropic resolution) sequences from a total of 80 MRI scans from 47 subjects were reviewed. White matter lesion (WML) masks were manually constructed from MPFLAIR and T1 maps (from MP2RAGE). Lesion volumes (normalized to intracranial volume) were compared to clinical characteristics and disability scales scores by Pearson or Spearman correlation, as appropriate. Relative correlation strength was compared by Fisher r- to z-transformation.
RESULTS: Normalized lesion volume was greater in MPFLAIR masks (median .005 [range, .001-.030]) than from T1 maps (median .003 [range, .000-.015]). However, lesion volumes between MPFLAIR and T1 maps were highly correlated (rho = .87, P < .001). WML masks from both modalities correlated with most disability measures with no significant difference in the strength of correlation.
CONCLUSIONS: 7T MPFLAIR and MP2RAGE T1 map-based WML volumes are highly intercorrelated and both correlate with disability. Thus, MP2RAGE may be a viable alternative to FLAIR-based methods for WML measurement on 7T MRI in MS research.
© 2020 American Society of Neuroimaging.

Entities:  

Keywords:  FLAIR; MP2RAGE; MRI; Multiple sclerosis

Mesh:

Year:  2020        PMID: 32569408      PMCID: PMC8080854          DOI: 10.1111/jon.12718

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  31 in total

1.  SA2RAGE: a new sequence for fast B1+ -mapping.

Authors:  Florent Eggenschwiler; Tobias Kober; Arthur W Magill; Rolf Gruetter; José P Marques
Journal:  Magn Reson Med       Date:  2011-08-29       Impact factor: 4.668

2.  High-resolution magnetization-prepared 3D-FLAIR imaging at 7.0 Tesla.

Authors:  Fredy Visser; Jaco J M Zwanenburg; Johannes M Hoogduin; Peter R Luijten
Journal:  Magn Reson Med       Date:  2010-07       Impact factor: 4.668

3.  New high dielectric constant materials for tailoring the B1+ distribution at high magnetic fields.

Authors:  K Haines; N B Smith; A G Webb
Journal:  J Magn Reson       Date:  2010-01-11       Impact factor: 2.229

4.  Seven-Tesla Magnetization Transfer Imaging to Detect Multiple Sclerosis White Matter Lesions.

Authors:  I-Jun Chou; Su-Yin Lim; Radu Tanasescu; Ali Al-Radaideh; Olivier E Mougin; Christopher R Tench; William P Whitehouse; Penny A Gowland; Cris S Constantinescu
Journal:  J Neuroimaging       Date:  2017-09-25       Impact factor: 2.486

Review 5.  MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS).

Authors:  F Barkhof
Journal:  Mult Scler       Date:  1999-08       Impact factor: 6.312

6.  Association of Cortical Lesion Burden on 7-T Magnetic Resonance Imaging With Cognition and Disability in Multiple Sclerosis.

Authors:  Daniel M Harrison; Snehashis Roy; Jiwon Oh; Izlem Izbudak; Dzung Pham; Susan Courtney; Brian Caffo; Craig K Jones; Peter van Zijl; Peter A Calabresi
Journal:  JAMA Neurol       Date:  2015-09       Impact factor: 18.302

7.  MP2RAGE, a self bias-field corrected sequence for improved segmentation and T1-mapping at high field.

Authors:  José P Marques; Tobias Kober; Gunnar Krueger; Wietske van der Zwaag; Pierre-François Van de Moortele; Rolf Gruetter
Journal:  Neuroimage       Date:  2009-10-09       Impact factor: 6.556

8.  Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis.

Authors:  A Traboulsee; J H Simon; L Stone; E Fisher; D E Jones; A Malhotra; S D Newsome; J Oh; D S Reich; N Richert; K Rammohan; O Khan; E-W Radue; C Ford; J Halper; D Li
Journal:  AJNR Am J Neuroradiol       Date:  2015-11-12       Impact factor: 3.825

9.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

10.  Brain tissue segmentation based on MP2RAGE multi-contrast images in 7 T MRI.

Authors:  Uk-Su Choi; Hirokazu Kawaguchi; Yuichiro Matsuoka; Tobias Kober; Ikuhiro Kida
Journal:  PLoS One       Date:  2019-02-28       Impact factor: 3.240

View more
  3 in total

1.  7T MRI Differentiates Remyelinated from Demyelinated Multiple Sclerosis Lesions.

Authors:  Hadar Kolb; Martina Absinta; Erin S Beck; Seung-Kwon Ha; Yeajin Song; Gina Norato; Irene Cortese; Pascal Sati; Govind Nair; Daniel S Reich
Journal:  Ann Neurol       Date:  2021-09-02       Impact factor: 11.274

2.  Blood-brain barrier breakdown in non-enhancing multiple sclerosis lesions detected by 7-Tesla MP2RAGE ΔT1 mapping.

Authors:  Seongjin Choi; Margaret Spini; Jun Hua; Daniel M Harrison
Journal:  PLoS One       Date:  2021-04-26       Impact factor: 3.240

3.  Association of retinal atrophy with cortical lesions and leptomeningeal enhancement in multiple sclerosis on 7T MRI.

Authors:  Ryan Mizell; Hegang Chen; Jeffrey Lambe; Shiv Saidha; Daniel M Harrison
Journal:  Mult Scler       Date:  2021-06-14       Impact factor: 6.312

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.